Abstract | BACKGROUND: Venous thrombus resolution sets up an early intense inflammatory reaction, from which vein wall damage results. Tissue response to injury includes matrix metalloproteinase ( MMP) activation and extracellular matrix protein turnover. This study sought to determine the effect of exogenous MMP inhibition and its potential attenuation of early vein wall injury. METHODS: RESULTS:
Thrombus sizes were similar at days 2 and 7 for all three groups, while thrombus TNFalpha was increased in 2-day LMWH- and DOXY-treated groups (NaCl = 1.0 +/- 0.8, LWMH = 9 +/- 3, DOXY = 27 +/- 5 pg/mg protein, n = 6-8, p < 0.05) and at 7 days in the DOXY group (NaCl = 3.0 +/- 2.5, DOXY = 23 +/- 4.2 pg/mg protein, n = 5, p < 0.05). Vein wall stiffness at 7 days was less with LMWH treatment, but not with DOXY, compared to controls (NaCl = 0.33 +/- 0.05, LMWH = 0.17 +/- 0.03, DOXY = 0.43 +/- 0.09 N/mm, n = 5-7, p < 0.05). Vessel-wall IL-1 beta was reduced only in the DOXY group at 7 days (NaCl = 26 +/- 3, LMWH = 38 +/- 17, DOXY = 6 +/- 3 pg/mg protein, n = 4-6, p < 0.05), as was the IT score versus controls (NaCl = 2.2 +/- 0.6, LMWH =1.7 +/- 0.3, DOXY = 0.8 +/- 0.20, n = 4-6, p < 0.05). Zymographic MMP9 activity was significantly reduced at 2 days in the LMWH and DOXY groups (NaCl = 85 +/- 24, LMWH = 23 +/- 7( *), DOXY = 13 +/- 5 U/mg protein, n = 6-8, p < 0.05). MMP2 zymographic activity, thrombus monocyte cell counts, and D-dimer activity were not significantly different across groups. CONCLUSION: Treatment with LMWH or DOXY did not alter the size of deep vein thrombosis, mildly altered thrombus composition, and differentially affected vein wall injury, despite similar reductions in early MMP9 activity. Whether exogenous MMP inhibition affects long-term vein wall fibrosis will require further study.
|
Authors | Vikram Sood, Cathy Luke, Erin Miller, Mayo Mitsuya, Gilbert R Upchurch Jr, Thomas W Wakefield, Dan D Myers, Peter K Henke |
Journal | Annals of vascular surgery
(Ann Vasc Surg)
Vol. 24
Issue 2
Pg. 233-41
(Feb 2010)
ISSN: 1615-5947 [Electronic] Netherlands |
PMID | 20142002
(Publication Type: Comparative Study, Journal Article, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't)
|
Copyright | Copyright 2010 Annals of Vascular Surgery Inc. Published by Elsevier Inc. All rights reserved. |
Chemical References |
- Enoxaparin
- Fibrin Fibrinogen Degradation Products
- Fibrinolytic Agents
- Interleukin-1beta
- Matrix Metalloproteinase Inhibitors
- Plasminogen Activator Inhibitor 1
- Protease Inhibitors
- Tumor Necrosis Factor-alpha
- fibrin fragment D
- Urokinase-Type Plasminogen Activator
- Matrix Metalloproteinase 2
- Mmp2 protein, rat
- Matrix Metalloproteinase 9
- Doxycycline
|
Topics |
- Animals
- Disease Models, Animal
- Doxycycline
(pharmacology)
- Elasticity
- Enoxaparin
(pharmacology)
- Fibrin Fibrinogen Degradation Products
(metabolism)
- Fibrinolytic Agents
(pharmacology)
- Fibrosis
- Interleukin-1beta
(metabolism)
- Ligation
- Male
- Matrix Metalloproteinase 2
(metabolism)
- Matrix Metalloproteinase 9
(metabolism)
- Matrix Metalloproteinase Inhibitors
- Plasminogen Activator Inhibitor 1
(metabolism)
- Protease Inhibitors
(pharmacology)
- Rats
- Rats, Sprague-Dawley
- Time Factors
- Tumor Necrosis Factor-alpha
(metabolism)
- Urokinase-Type Plasminogen Activator
(metabolism)
- Vena Cava, Inferior
(drug effects, metabolism, pathology, surgery)
- Venous Thrombosis
(drug therapy, metabolism, pathology)
|
|
Join CureHunter, for free Research Interface BASIC access!
Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease.
Find out why thousands of doctors, pharma researchers and patient activists
around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!
|